MedPath

Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic

Not Applicable
Recruiting
Conditions
Mild Cognitive Impairment
Interventions
Device: Neuro-World
Registration Number
NCT04920123
Lead Sponsor
University of Massachusetts, Amherst
Brief Summary

This study will evaluate the therapeutic efficacy of Neuro-World cognitive training games (Woorisoft, S. Korea) in patients with mild cognitive impairment.

Detailed Description

This study will be a cross-over randomized controlled trial.

Fifty participants will be enrolled and randomly assigned to group A or group B.

Group A will self-administer Neuro-World cognitive training games for 30 minutes a day, twice a week for 12 weeks in the home setting (i.e., intervention period). For the following 12 weeks, the participants will not engage in any therapist-supervised cognitive therapies (i.e., no-intervention period).

Group B will not engage in any therapist-supervised cognitive therapies (i.e., no-intervention period). For the following 12 weeks, the participants will self-administer Neuro-World cognitive training games for 30 minutes a day, twice a week in the home setting (i.e., intervention period).

All the participants in both groups will receive phone calls twice a week to 1) provide feedback on their adherence to Neuro-World cognitive training (during the intervention period) and 2) learn any significant changes in the level of their daily activities (during the no-intervention period and the intervention period).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Seventeen points or greater and smaller than twenty-six points on the Montreal Cognitive Assessment (MoCA)
  • Fifty-five years old and above
  • Minimal technological literacy (i.e. ability to use a tablet independently)
  • Having a computer for online videoconferencing-based communication (necessary for online cognitive assessments)
Exclusion Criteria
  • Confounding neurological and psychiatric disorders
  • History of traumatic brain injury
  • Clinically known hearing or vision impairment
  • Severe upper-limb motor impairments that could impact the use of mobile devices
  • Clinical presentations suggestive of dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, or vascular parkinsonism
  • Diagnosis of dementia
  • Major depression
  • Any significant upper-limb impairment that could affect tablet use
  • Participation in any other therapist-supervised cognitive training

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Game InterventionNeuro-WorldStudy participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).
Primary Outcome Measures
NameTimeMethod
Montreal Cognitive Assessment (MoCA)30 minutes

MoCA scores range between 0 and 30. Higher scores indicate better cognitive function.

Secondary Outcome Measures
NameTimeMethod
Geriatric Depression Scale (GDS)5 minutes

GDS scores range between 0 and 15. Higher scores indicate more severe depression.

Digit Forward Span (DFS)5 minutes

DFS scores range between 0 and 14. Higher scores indicate better cognitive function.

Mini-Mental State Examination (MMSE)10 minutes

MMSE scores range between 0 and 30. Higher scores indicate better cognitive function.

Short Form 36 (SF-36)10 minutes

SF-36 scores range between 0 and 100. Higher scores indicate more favorable health states.

Digit Backward Span (DBS)5 minutes

DBS scores range between 0 and 14. Higher scores indicate better cognitive function.

Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for mild cognitive impairment patients (ADCS/MCI/ADL24)10 minutes

ADCS/MCI/ADL24 scores range between 0 and 69. Higher scores indicate greater levels of performance in activities of daily living.

Trial Locations

Locations (2)

The State University of New Jersey, Rutgers

🇺🇸

Newark, New Jersey, United States

University of Massachusetts, Amherst

🇺🇸

Amherst, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath